Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.28), $0.12 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $0 , versus $0 reported last year.

Third Quarter Highlights:

• Awarded a $16 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 3 trial of NurOwn® in ALS. A milestone payment of $5.5 million, representing approximately 30% of the grant, has been received. The trial will evaluate the safety and efficacy of repeated administrations of NurOwn® and is expected to enroll approximately 200 participants.
• Entered into agreements with Massachusetts General Hospital, California Pacific Medical Center, and University of California-Irvine Medical Center to participate in the Phase 3 trial of NurOwn® in ALS.
• Signed a definitive agreement with Worldwide Clinical Trials as the clinical research organization (CRO) for the Phase 3 NurOwn® trial.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.